Hardouin S, Hossenlopp P, Segovia B, Seurin D, Portolan G, Lassarre C, Binoux M
Unité 142 de l'Institut National de la Santé et de la Recherche Médicale, Paris, France.
Eur J Biochem. 1987 Dec 30;170(1-2):121-32. doi: 10.1111/j.1432-1033.1987.tb13676.x.
Circulating insulin-like growth factors (IGFs) are bound to specific, high-affinity binding proteins (BPs), and form complexes with relative molecular masses of about 150,000 ('large' complex) and 40,000 ('small' complex). The large complex appears to be under growth-hormone control and its proportions vary with those of the IGFs. Molecular heterogeneity among the binding proteins was revealed by polyacrylamide gel electrophoresis (SDS-PAGE) of serum in which they were cross-linked to 125I-labelled IGF I or II. Out of the six specific bands observed, of 150,000, 120,000, 49,000, 40,000 and 37,000 Mr, the last three appeared in both complexes, whereas the first three were visible only in the large complex. Some or all of the 49,000-37,000-Mr species may constitute the subunits of 150,000-Mr and/or 120,000-Mr IGF-BP complexes. With electrophoresis followed by transfer onto nitrocellulose and incubation with either 125I-labelled IGF I or II (western blot), the different binding proteins were identified per se. There were five molecular forms with Mr of 41,500, 38,500, 34,000, 30,000 and 24,000. In normal serum the 41,500 and 38,500-Mr forms were the major binding proteins. They appeared in both complexes, but were predominant in the large complex where they constitute the elementary binding units. These two proteins therefore bind to IGFs to form both 'monomeric' IGF-BP and 'oligomeric' (IGF-BP)n complexes. The 34,000, 30,000 and 24,000-Mr forms, by contrast, were visible only in the small complex. Different mechanisms appear to regulate the different binding proteins: in acromegalic serum the 41,500 and 38,500-Mr forms were augmented and the 34,000-Mr form diminished, whereas in hypopituitary serum the reverse was true and, in addition, the 30,000-Mr form was augmented. With chromatofocusing, the 34,000, 30,000 and 24,000-Mr forms eluted in three peaks between pH 6.0 and 4.0, whereas the 41,500 and 38,500-Mr forms eluted throughout the gradient, principally at pH 7.5 and 7.0. Competitive binding studies, done on binding proteins separated either by chromatofocusing or by SDS-PAGE and transfer onto nitrocellulose, revealed different affinities for the IGFs among the different molecular forms. The 41,500 and 24,000-Mr binding proteins preferentially bound IGF I and the 38,500, 34,000 and 30,000-Mr proteins preferentially bound IGF II. Our findings demonstrate the molecular heterogeneity of the binding proteins and the existence of a relationship between their structure and their affinities for the IGFs.(ABSTRACT TRUNCATED AT 400 WORDS)
循环中的胰岛素样生长因子(IGFs)与特定的高亲和力结合蛋白(BPs)相结合,形成相对分子质量约为150,000的复合物(“大”复合物)和40,000的复合物(“小”复合物)。大复合物似乎受生长激素控制,其比例随IGFs的比例而变化。通过对血清进行聚丙烯酰胺凝胶电泳(SDS-PAGE)揭示了结合蛋白之间的分子异质性,在血清中它们与125I标记的IGF I或II交联。在观察到的150,000、120,000、49,000、40,000和37,000 Mr的六个特定条带中,后三个条带出现在两种复合物中,而前三个条带仅在大复合物中可见。49,000 - 37,000 Mr的某些或所有种类可能构成150,000 Mr和/或120,000 Mr IGF-BP复合物的亚基。通过电泳,然后转移到硝酸纤维素膜上,并用125I标记的IGF I或II孵育(蛋白质印迹法),可直接鉴定出不同的结合蛋白。有五种分子形式,相对分子质量分别为41,500、38,500、34,000、30,000和24,000。在正常血清中,41,500和38,500 Mr的形式是主要的结合蛋白。它们出现在两种复合物中,但在大复合物中占主导地位,在大复合物中它们构成基本的结合单位。因此,这两种蛋白质与IGFs结合形成“单体”IGF-BP和“寡聚体”(IGF-BP)n复合物。相比之下,34,000、30,000和24,000 Mr的形式仅在小复合物中可见。不同的机制似乎调节不同的结合蛋白:在肢端肥大症患者的血清中,41,500和38,500 Mr的形式增加,34,000 Mr的形式减少,而在垂体功能减退患者的血清中情况相反,此外,30,000 Mr的形式增加。通过色谱聚焦法,34,000、30,000和24,000 Mr的形式在pH 6.0至4.0之间的三个峰中洗脱,而41,500和38,500 Mr 的形式在整个梯度中洗脱,主要在pH 7.5和7.0处。对通过色谱聚焦法或SDS-PAGE分离并转移到硝酸纤维素膜上的结合蛋白进行的竞争性结合研究表明,不同分子形式对IGFs具有不同的亲和力。41,500和24,000 Mr的结合蛋白优先结合IGF I,而38,500、34,000和30,000 Mr的蛋白优先结合IGF II。我们的研究结果证明了结合蛋白的分子异质性以及它们的结构与对IGFs的亲和力之间存在的关系。(摘要截短至400字)